{"id":"W2591044260","doi":"10.1200/jco.2013.31.15_suppl.4032","title":"Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Temsirolimus; Internal medicine; Everolimus; Bevacizumab; Sunitinib; Clinical endpoint; Phases of clinical research; Progression-free survival; Oncology; Interim analysis; Progressive disease; Response Evaluation Criteria in Solid Tumors; Leukopenia; Gastroenterology; Chemotherapy; Clinical trial; Cancer; PI3K/AKT/mTOR pathway; Discovery and development of mTOR inhibitors","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.001100831,0.0002007549,0.002216395,0.0003556564,0.00003251301,0.00001094873,0.0002275923,0.00002525505,0.0002917146],"category_scores_gemma":[0.01341602,0.0001405704,0.000335182,0.0002038324,0.0004293619,0.0002782408,0.0001830345,0.001399071,0.00001483775],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007644408,"about_ca_system_score_gemma":0.0006358575,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008763134,"about_ca_topic_score_gemma":0.00003517974,"domain_scores_codex":[0.9943392,0.0007970099,0.00353299,0.0002804958,0.000572701,0.0004775945],"domain_scores_gemma":[0.9935961,0.003351538,0.001690074,0.0002852185,0.0004353889,0.00064169],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6071116,0.03729826,0.06354614,0.0004644484,0.0004751779,0.06225744,0.0000902721,0.00001165527,0.009106319,0.00008675201,0.006832292,0.2127196],"study_design_scores_gemma":[0.6123872,0.2687645,0.06220287,0.0002881019,0.0003492312,0.009866594,0.0002131502,0.0007782636,0.001261608,0.0005501741,0.04313679,0.0002015237],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9889854,0.0003297307,0.000004047285,0.008170066,0.0006771776,0.001078175,0.000003718871,0.000008603059,0.0007431096],"genre_scores_gemma":[0.9951963,0.001020129,0.001402505,0.001098548,0.0008058092,0.00002382588,0.000001194333,0.00002655986,0.000425123],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2314662,"threshold_uncertainty_score":0.9948944,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0922024343955625,"score_gpt":0.4789803547000079,"score_spread":0.3867779203044455,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}